LAG‐3 and PD‐1 are commonly coexpressed on CD8+ TILs, thus contributing to tumor‐mediated immune suppression [424, 426, 427], and blocking both receptors can synergistically reduce tumor growth and strengthen antitumor immunity [426]. The gene discussed is LAG3; the disease is neoplasm.